Placebo-Controlled Dose-Ranging Phase 2 Study of Subcutaneously Administered LHRH Antagonist Cetrorelix in Patients with Symptomatic Benign Prostatic Hyperplasia

Emerging Treatment Options for Benign Prostatic Obstruction

“…In a phase 2, placebo-controlled, dose-ranging study, cetrorelix treatment was associated with improvements in IPSS and QoL, an increase in Qmax, and a slight reduction in PV with no reported effect on erectile function [32]. Two subsequent phase 3 trials failed to show a beneficial effect of cetrorelix over placebo, but a third phase 3 efficacy study in North America revealed a 6-point improvement in mean IPSS scores at week 26 with only mild and transient adverse events [4].…”

Hormonal manipulation of benign prostatic hyperplasia

“…The LHRH antagonist, cetrorelix, has beneficial effects on LUTS in BPH patients [53][54][55][56][57]. A study with cetrorelix showed short-term administration produced long-term LUTS improvement and decreased prostate volume [53].…”

“…This demonstrates that cetrorelix is well tolerated and produces long-term improvement. In a phase II multidose study [55], cetrorelix was well tolerated, effective with rapid onset and persistent response. Debruyne et al [56] compared the efficacy of four doses of cetrorelix in a sustained release formulation allowing more convenient administration.…”

Late - Onset Hypogonadism - New Point of View

“…In the treatment of BPH, other drugs have been used as well to decrease LH synthesis for more than 20 years. This effect has been achieved by LHRH analogues or LHRH agonists (Oesterling, 1991, Reissmann, et al, 2000, Debruyne, et al, 2008. This therapy, however, has significant disadvantages.…”

“…However, the losses of testosterone and long-term E2 deficiency result in the situation in which the hypothalamus and pituitary gland can become prostate's greatest enemies. Therefore, modern hormonal medications used to treat BPH have selfstimulation points in the lateral hypothalamus (Oesterling, 1991, Reissmann, et al, 2000, Debruyne, et al, 2008.…”